HK1211844A1 - Treatment of pulmonary disease - Google Patents

Treatment of pulmonary disease Download PDF

Info

Publication number
HK1211844A1
HK1211844A1 HK15112720.5A HK15112720A HK1211844A1 HK 1211844 A1 HK1211844 A1 HK 1211844A1 HK 15112720 A HK15112720 A HK 15112720A HK 1211844 A1 HK1211844 A1 HK 1211844A1
Authority
HK
Hong Kong
Prior art keywords
compound
lung
pulmonary
hydrogen
pharmaceutically acceptable
Prior art date
Application number
HK15112720.5A
Other languages
English (en)
Chinese (zh)
Inventor
‧普魯贊斯基
M‧普鲁赞斯基
盧西亞諾‧阿多裡尼
卢西亚诺‧阿多里尼
Original Assignee
英特赛普特医药品公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49753520&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1211844(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 英特赛普特医药品公司 filed Critical 英特赛普特医药品公司
Publication of HK1211844A1 publication Critical patent/HK1211844A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK15112720.5A 2012-11-28 2013-11-26 Treatment of pulmonary disease HK1211844A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261730749P 2012-11-28 2012-11-28
US61/730,749 2012-11-28
PCT/US2013/072038 WO2014085474A1 (en) 2012-11-28 2013-11-26 Treatment of pulmonary disease

Publications (1)

Publication Number Publication Date
HK1211844A1 true HK1211844A1 (en) 2016-06-03

Family

ID=49753520

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15112720.5A HK1211844A1 (en) 2012-11-28 2013-11-26 Treatment of pulmonary disease

Country Status (19)

Country Link
US (3) US20140148428A1 (https=)
EP (1) EP2925328A1 (https=)
JP (1) JP6270171B2 (https=)
KR (1) KR102106186B1 (https=)
CN (1) CN104853758A (https=)
AU (1) AU2013352288B2 (https=)
BR (1) BR112015012312A2 (https=)
CA (1) CA2891348C (https=)
CL (1) CL2015001442A1 (https=)
HK (1) HK1211844A1 (https=)
IL (1) IL239025B (https=)
MX (1) MX2015006710A (https=)
MY (1) MY170802A (https=)
NZ (1) NZ708501A (https=)
PH (1) PH12015501108A1 (https=)
RU (1) RU2693382C2 (https=)
SG (1) SG11201503697TA (https=)
TW (1) TWI636786B (https=)
WO (1) WO2014085474A1 (https=)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3071696T1 (sl) 2013-11-22 2019-11-29 Mina Therapeutics Ltd C/EBP alfa kratko delujoči RNA sestavki in postopki uporabe
WO2016045480A1 (zh) * 2014-09-28 2016-03-31 上海源力生物技术有限公司 一种奥贝胆酸的制备方法
US10538550B2 (en) 2014-11-19 2020-01-21 NZP UK Limited 6.alpha.-alkyl-3,7-dione steroids as intermediates for the production of steroidal FXR modulators
US10131688B2 (en) 2014-11-19 2018-11-20 NZP UK Limited 5.beta.-6-alkyl-7-hydroxy-3-one steroids as intermediates for the production of steroidal FXR modulators
TWI688571B (zh) * 2014-11-19 2020-03-21 英商Ｎｚｐ英國有限公司 化合物（四）
KR102526631B1 (ko) * 2014-11-19 2023-04-27 엔제트피 유케이 리미티드 스테로이드 fxr 조절인자를 제조하기 위한 중간체로서의 6-알킬-7-하이드록시-4-엔-3-온 스테로이드
CN105348365A (zh) * 2014-12-03 2016-02-24 四川百利药业有限责任公司 一种胆酸衍生物及其制备方法、药物组合物和用途
CN105801653B (zh) * 2014-12-30 2018-04-17 苏州晶云药物科技有限公司 奥贝胆酸的晶型a及其制备方法
CZ2015504A3 (cs) * 2015-07-16 2017-01-25 Zentiva, K.S. Krystalické formy obeticholové kyseliny
CN105085597B (zh) * 2015-08-28 2017-03-29 成都百裕制药股份有限公司 一种无定型奥贝胆酸的制备方法
EP3353189A4 (en) * 2015-09-24 2019-06-19 Intercept Pharmaceuticals, Inc. METHOD AND INTERMEDIATE PRODUCTS FOR THE PREPARATION OF GALLENIC ACID DERIVATIVES
EP3981779A1 (en) * 2015-10-07 2022-04-13 Intercept Pharmaceuticals, Inc. Farnesoid x receptor modulators
CN106589039B (zh) * 2015-10-15 2019-12-17 苏州朗科生物技术股份有限公司 一种奥贝胆酸的制备方法及相关化合物
CN106589038A (zh) * 2015-10-15 2017-04-26 重庆医药工业研究院有限责任公司 一种制备3α,7α-二羟基-6α-乙基-5β-胆烷酸的方法
CN106668027A (zh) * 2015-11-05 2017-05-17 中美华世通生物医药科技（武汉）有限公司 奥贝胆酸药物组合物及其制备方法
CN105399793A (zh) * 2015-12-24 2016-03-16 北京康立生医药技术开发有限公司 一种胆烷酸的制备方法
ES2909907T3 (es) 2016-02-10 2022-05-10 Dr Reddys Laboratories Ltd Proceso de purificación que implica la sal de amina del ácido obeticólico
JPWO2017170858A1 (ja) * 2016-03-31 2019-02-14 インターセプト ファーマシューティカルズ， インコーポレイテッド 溶出性に優れた経口製剤
WO2017180577A1 (en) * 2016-04-13 2017-10-19 Intercept Pharmaceuticals, Inc. Methods of treating cancer
GB201608776D0 (en) 2016-05-18 2016-06-29 Dextra Lab Ltd Methods and compounds
GB201608777D0 (en) 2016-05-18 2016-06-29 Dextra Lab Ltd Compounds
WO2017208165A1 (en) * 2016-06-01 2017-12-07 Dr. Reddy’S Laboratories Limited Process for preparation of obeticholic acid
CN106046095B (zh) * 2016-06-06 2017-02-22 南京理工大学 奥贝胆酸的合成方法
CA3038534A1 (en) * 2016-09-30 2018-04-05 Intercept Pharmaceuticals, Inc. Crystalline forms of a bile acid derivative
CN108117579A (zh) * 2016-11-29 2018-06-05 昆明积大制药股份有限公司 奥贝胆酸及其中间体的制备方法
TW201832768A (zh) * 2017-03-07 2018-09-16 英特賽普醫藥品公司 治療癌症的方法
WO2019048632A1 (en) 2017-09-08 2019-03-14 Mina Therapeutics Limited STABILIZED COMPOSITIONS OF SMALL ACTIVATORY RNA (PARNA) OF HNF4A AND METHODS OF USE
KR20190030805A (ko) * 2017-09-14 2019-03-25 경상대학교산학협력단 폐고혈압 예방 또는 치료용 흡입제, 및 이의 투여방법
EP3705487B1 (en) * 2017-11-02 2022-10-26 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Method for preparing cholic acid compound
KR20210038877A (ko) 2018-07-25 2021-04-08 노파르티스 아게 Nlrp3 인플라마좀 억제제
AR119731A1 (es) 2019-05-17 2022-01-05 Novartis Ag Inhibidores del inflamasoma nlrp3
TW202122078A (zh) 2019-09-06 2021-06-16 瑞士商諾華公司 使用lta4h抑制劑治療肝臟疾病之方法
KR20220150270A (ko) 2019-10-07 2022-11-10 칼리오페, 인크. Gpr119 효능제
TW202140440A (zh) 2020-02-28 2021-11-01 美商克力歐普股份有限公司 Gpr40激動劑
CN113318114B (zh) * 2020-02-28 2023-02-17 广州市赛普特医药科技股份有限公司 小分子化合物在治疗肺上皮细胞损伤和/或血管内皮细胞损伤介导的疾病中的用途
WO2021236617A1 (en) 2020-05-19 2021-11-25 Kallyope, Inc. Ampk activators
CN116390925A (zh) 2020-06-26 2023-07-04 卡尔优普公司 Ampk活化剂
UY40374A (es) 2022-08-03 2024-02-15 Novartis Ag Inhibidores de inflamasoma nlrp3

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2064336B (en) 1979-12-06 1984-03-14 Glaxo Group Ltd Device for dispensing medicaments
US4353656A (en) 1980-10-14 1982-10-12 Xerox Corporation Moving coil, multiple energy print hammer system including a closed loop servo
DE3274065D1 (de) 1981-07-08 1986-12-11 Draco Ab Powder inhalator
US4778054A (en) 1982-10-08 1988-10-18 Glaxo Group Limited Pack for administering medicaments to patients
GB2169265B (en) 1982-10-08 1987-08-12 Glaxo Group Ltd Pack for medicament
GB2129691B (en) 1982-10-08 1987-08-05 Glaxo Group Ltd Devices for administering medicaments to patients
AU591152B2 (en) 1985-07-30 1989-11-30 Glaxo Group Limited Devices for administering medicaments to patients
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
US5977095A (en) * 1993-03-09 1999-11-02 University Of Utah Research Foundation Methods for preventing progressive tissue necrosis, reperfusion injury, bacterial translocation and respiratory distress syndrome
EP0813490B1 (en) 1995-03-10 2000-07-12 Minnesota Mining And Manufacturing Company Aerosol valves
GB9700226D0 (en) 1997-01-08 1997-02-26 Glaxo Group Ltd Inhalation device
US6632666B2 (en) 2000-01-14 2003-10-14 Biolife Solutions, Inc. Normothermic, hypothermic and cryopreservation maintenance and storage of cells, tissues and organs in gel-based media
AU2002308295B2 (en) * 2001-03-12 2007-08-23 Intercept Pharmaceuticals, Inc. Steroids as agonists for FXR
US20070015796A1 (en) * 2003-09-26 2007-01-18 Smithkline Beecham Corporation Compositions and methods for treatment of fibrosis
EP1734970B1 (en) * 2004-03-12 2014-12-31 Intercept Pharmaceuticals, Inc. Treatment of fibrosis using fxr ligands
ITMI20050912A1 (it) 2005-05-19 2006-11-20 Erregierre Spa Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici
PT2040713E (pt) * 2006-06-27 2014-10-13 Intercept Pharmaceuticals Inc Para a prevenção ou o tratamento de doenças ou estados clínicos mediados por fxr
CN101479249B (zh) * 2006-06-29 2012-10-10 霍夫曼-拉罗奇有限公司 苯并咪唑衍生物、其制备方法、它们作为fxr激动剂的用途及含有它们的药物制剂
EA020310B1 (ru) * 2008-07-30 2014-10-30 Интерсепт Фармасьютикалз, Инк. Модуляторы рецептора tgr5 и их применение
CN102282157B (zh) * 2008-11-19 2017-02-22 英特塞普特医药品公司 G蛋白偶联受体5(tgr5)调节剂及其使用方法
US20110257139A1 (en) * 2008-12-19 2011-10-20 Royal College Of Surgeons In Ireland Treatment of diarrhoea
EP2470553B1 (en) * 2009-08-25 2024-06-19 Qing Bile Therapeutics Inc. Polyhydroxylated bile acids for treatment of biliary disorders
US9416151B2 (en) * 2010-08-25 2016-08-16 Lurong ZHANG Use of glycyrrhetinic acid, glycyrrhizic acid and related compounds for prevention and/or treatment of pulmonary fibrosis
NZ734451A (en) * 2012-06-19 2018-12-21 Intercept Pharmaceuticals Inc Preparation, uses and solid forms of obeticholic acid

Also Published As

Publication number Publication date
NZ708501A (en) 2019-03-29
RU2693382C2 (ru) 2019-07-02
JP6270171B2 (ja) 2018-01-31
KR102106186B1 (ko) 2020-05-04
IL239025A0 (en) 2015-07-30
RU2015122027A (ru) 2017-01-10
CL2015001442A1 (es) 2015-08-28
BR112015012312A2 (pt) 2017-07-11
US20140148428A1 (en) 2014-05-29
TW201434469A (zh) 2014-09-16
WO2014085474A1 (en) 2014-06-05
JP2016500111A (ja) 2016-01-07
US20180064729A1 (en) 2018-03-08
PH12015501108B1 (en) 2015-08-17
KR20150089052A (ko) 2015-08-04
CA2891348A1 (en) 2014-06-05
CN104853758A (zh) 2015-08-19
CA2891348C (en) 2020-04-28
AU2013352288A1 (en) 2015-06-04
PH12015501108A1 (en) 2015-08-17
AU2013352288B2 (en) 2017-11-23
MX2015006710A (es) 2016-01-15
IL239025B (en) 2021-04-29
SG11201503697TA (en) 2015-06-29
US20160213689A1 (en) 2016-07-28
EP2925328A1 (en) 2015-10-07
TWI636786B (zh) 2018-10-01
MY170802A (en) 2019-08-28

Similar Documents

Publication Publication Date Title
HK1211844A1 (en) Treatment of pulmonary disease
CA2815029A1 (en) Imidazo[1,2-b]pyridazine and imidazo[4,5-b]pyridine derivatives as jak inhibitors
CA2951337C (en) Ppar compounds for use in the treatment of fibrotic diseases
EA022358B1 (ru) НОВЫЕ ПРОИЗВОДНЫЕ ЦИКЛОГЕКСИЛАМИНА, ОБЛАДАЮЩИЕ АГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ ПО ОТНОШЕНИЮ К β2 АДРЕНЕРГИЧЕСКОМУ РЕЦЕПТОРУ И АНТАГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ ПО ОТНОШЕНИЮ К M3 МУСКАРИНОВОМУ РЕЦЕПТОРУ
EP2427417B1 (en) Salts of 3-pentylphenylacetic acid and pharmaceutical uses thereof
JP2016540017A (ja) ｓＧＣ刺激物質
JPH03178929A (ja) 炎症及びアレルギー治療用化合物
JP2022507118A (ja) 呼吸器疾患の処置のための化合物及び組成物
CA3030232A1 (en) Pyrimidinone derivatives and uses thereof to neutralize the biological activity of chemokines
JP2009503101A (ja) Ｍ３ムスカリン性アセチルコリン受容体アンタゴニスト
TW201625641A (zh) Ｎａｍｐｔ抑制劑及方法
JP2025502842A (ja) 薬学的に活性な化合物としての使用のための（５ｓ）－｛［２－（４－カルボキシフェニル）エチル］［２－（２－｛［３－クロロ－４’－（トリフルオロメチル）ビフェニル－４－イル］メトキシ｝フェニル）エチル］アミノ｝－５，６，７，８－テトラヒドロキノリン－２－カルボン酸及びその結晶形態を調製するための方法
CN112076180B (zh) 抗高血压的多元醇化合物及其衍生物
KR102570702B1 (ko) 퀴누클리딘 유도체
AU2023273614A1 (en) Methods of treatment for cystic fibrosis
TW200303754A (en) Pharmaceutical combination
JP2019527709A (ja) オーレオバシジン誘導体および合成方法
WO2022175425A1 (en) Inhaled mtor kinase inhibitors for use in the treatment or the prevention of a respiratory rna virus infection
NZ624784B2 (en) New cyclohexylamine derivatives having ?2 adrenergic agonist and m3 muscarinic antagonist activities